Keywords: آلومتوزومب; Cytokine release syndrome; CRS; Immunotoxicity; Cytokine release assay; Anti-CD28; Alemtuzumab; OKT3;
مقالات ISI آلومتوزومب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آلومتوزومب; lung transplant; chronic lung allograft dysfunction; photopheresis; alemtuzumab; rejection;
Keywords: آلومتوزومب; Multiple sclerosis; Alemtuzumab; Dimethyl fumarate; Fingolimod; Natalizumab; Teriflunomide; Adverse effects; Depression; Anxiety; Systematic review;
Keywords: آلومتوزومب; Alemtuzumab; Reduced-intensity conditioning; Pharmacokinetics; Allogeneic hematopoietic cell transplantation; HCT; Bone marrow transplantation; BMT;
Keywords: آلومتوزومب; Multiple sclerosis; Dimethyl fumarate; Teriflunomide; Alemtuzumab;
Keywords: آلومتوزومب; Alemtuzumab; Multiple sclerosis; Polymorphonuclear neutrophils; Neutropenia;
Keywords: آلومتوزومب; Alemtuzumab; T cell depletion; Graft-versus-host disease; Conditioning regimens;
Keywords: آلومتوزومب; DMT; disease modifying therapy; EDSS; Expanded Disability Status Scale; MRI; magnetic resonance imaging; MS; multiple sclerosis; Relapsing-remitting multiple sclerosis; Disease modifying therapy; Natalizumab; Fingolimod; Alemtuzumab; Systematic review;
Keywords: آلومتوزومب; Alemtuzumab; Graft-versus-host disease (GVHD); Steroid-refractory acute graft-versus-host disease (SR-aGVHD); Alemtuzumab in children; Alemtuzumab for GVHD;
Keywords: آلومتوزومب; Alemtuzumab; Disability; Disease-modifying therapy; Expanded Disability Status Scale; Functional systems; Multiple sclerosis;
Keywords: آلومتوزومب; Sickle cell disease; Adult; Alemtuzumab; Quality of life; Allogeneic transplantation; ABO mismatch
Keywords: آلومتوزومب; Alemtuzumab; Ibrutinib; Idelalisib; Obinutuzumab; Ofatumumab; Rituximab;
Keywords: آلومتوزومب; Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Minimal residual disease; Small lymphocytic lymphoma
Keywords: آلومتوزومب; Antithymocyte globulin; Alemtuzumab; Hematopoietic stem cell transplantation; Immune reconstitution; Survival; Children
Keywords: آلومتوزومب; Primary immune deficiency; Bone marrow transplantation; Hematopoietic cell transplantation; Reduced-intensity conditioning; Alemtuzumab; Mixed chimerism;
Keywords: آلومتوزومب; Hemophagocytic lymphohistiocytosis; Stem cell transplantation; Alemtuzumab; Chimerism; Treatment;
Keywords: آلومتوزومب; Acute myelogenous leukemia; Myelodysplastic syndrome; Reduced intensity; Transplantatiom; Alemtuzumab
Keywords: آلومتوزومب; Primary immunodeficiency; Cord blood transplantation; Immune reconstitution; Serotherapy; Alemtuzumab
Keywords: آلومتوزومب; Aplastic anemia; Alemtuzumab; Allogeneic transplantation; Graft-versus-host disease; Survival
Keywords: آلومتوزومب; Acute transplant glomerulopathy; Transplant glomerulitis; Alemtuzumab; Monocyte; Macrophage; Kidney transplantation;
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis
Keywords: آلومتوزومب; CMV; Alemtuzumab; Opportunistic infections; Multiple sclerosis;
CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity
Keywords: آلومتوزومب; Stem cell transplantation; Allogeneic transplantation; Alemtuzumab; Cytomegalovirus infections; T-lymphocytes; Flow cytometry; Cell separation; Chimerism;
Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab
Keywords: آلومتوزومب; Multiple sclerosis; Natalizumab; Daclizumab; Alemtuzumab;
Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion
Keywords: آلومتوزومب; Alemtuzumab; Multiple sclerosis; Neutropenia; Septic shock;
Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab
Keywords: آلومتوزومب; Multiple Sclerosis; Fingolimod; Alemtuzumab; Rebound;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)
Keywords: آلومتوزومب; Alemtuzumab; Anti-CD20 monoclonal antibodies; Blinatumomab; Hepatitis B virus; Inebilizumab; Infection; Rituximab;
Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
Keywords: آلومتوزومب; Hematopoietic stem cell transplantation; Alemtuzumab; Aplastic anemia; T cells; Chimerism;
Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
Keywords: آلومتوزومب; Alemtuzumab; Infusion associated reactions; Multiple sclerosis;
Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8 years of follow-up
Keywords: آلومتوزومب; Renal transplantation; Rabbit antithymocyte globulin; Daclizumab; Alemtuzumab; Tacrolimus; Enteric-coated mycophenolate sodium; Steroid avoidance; Biopsy-proven acute rejection; Graft survival;
T-cell Prolymphocytic Leukemia
Keywords: آلومتوزومب; T-cell prolymphocytic leukemia; T-cell; Leukemia; Alemtuzumab;
Lack of CD4Â + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
Keywords: آلومتوزومب; Alemtuzumab; Multiple sclerosis; Treatment response; CD4Â + lymphocytes; Immune reconstitution;
A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor
Keywords: آلومتوزومب; Pediatrics; Nonmalignant diseases; reduced toxicity; alemtuzumab
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience
Keywords: آلومتوزومب; Alemtuzumab; GVHD; HSCT; T-PLL
Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion
Keywords: آلومتوزومب; Acute myeloid leukemia; Stem cell transplantation; Reduced-intensity conditioning; Alemtuzumab; Re-188 radioimmunotherapy
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis
Keywords: آلومتوزومب; MS; multiple sclerosis; EAE; experimental autoimmune encephalomyelitis; mu; murine; SMEP; spinal motor evoked potential; Multiple sclerosis; Experimental autoimmune encephalomyelitis; CD52; Mouse; Alemtuzumab;
Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review
Keywords: آلومتوزومب; Autoimmune chronic uveitis; Alemtuzumab; Anakinra; Rituximab; Abatacept; Tocilizumab;
Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis
Keywords: آلومتوزومب; Myositis; HTLV-1; Alemtuzumab; Anti-CD52; Crohn-like disease; Myelopathy/tropical spastic paraparesis;
Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
Keywords: آلومتوزومب; Allogeneic hematopoietic cell transplantation; Acute graft-versus-host disease; Antibody therapy; Alemtuzumab
Alemtuzumab induced ST-segment elevation and acute myocardial dysfunction
Keywords: آلومتوزومب; Alemtuzumab; Cardiotoxicity; Acute myocardial dysfunction; Chemotherapy; Apical ballooning syndrome;
Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab
Keywords: آلومتوزومب; Valganciclovir; Prophylaxis; Epstein Barr virus; Cytomegalovirus; Alemtuzumab
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked Lymphoproliferative Disease Type 1
Keywords: آلومتوزومب; X-linked lymphoproliferative disease; XLP; SLAM-associated protein; SH2D1A; Bone marrow transplant; Allogeneic hematopoietic cell transplant; Alemtuzumab; Reduced-intensity conditioning
Rationnel et efficacité du ciblage du CD52Â dans la myosite associée au HTLV-1
Keywords: آلومتوزومب; Myosite; HTLV-1; Alemtuzumab; Anti-CD52; Pseudomaladie de Crohn; Myélopathie; Paraparésie spastique tropicale;
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
Keywords: آلومتوزومب; Chronic lymphocytic leukemia; CLL; Young; Biology; Fludarabine; Alemtuzumab;
Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies
Keywords: آلومتوزومب; Reduced-intensity; Alemtuzumab; Matched-related; Matched-unrelated; Haploidentical
ReviewMode of action and clinical studies with alemtuzumab
Keywords: آلومتوزومب; Multiple sclerosis; Immunotherapy; Alemtuzumab; Clinical trials;
Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma
Keywords: آلومتوزومب; Follicular lymphoma; Hematopoietic stem cell transplantation; BEAM; Alemtuzumab;
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant
Keywords: آلومتوزومب; Reduced intensity transplant; T cell chimerism; Alemtuzumab;
Immune status following alemtuzumab treatment in human CD52 transgenic mice
Keywords: آلومتوزومب; Alemtuzumab; Immune status; CD52; Multiple sclerosis;
Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys
Keywords: آلومتوزومب; ATG; anti-thymocyte globulin; LN; lymph node(s); MFI; mean fluorescence intensity; NHP; non-human primate; PBMC; peripheral blood mononuclear cells; Tmem; memory T cell(s); Tn; naïve T cell(s); Alemtuzumab; Transplantation; Lymph node; Memory T cell; NaÃ
Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia
Keywords: آلومتوزومب; Leukemia; Aspergillus fumigatus; Alemtuzumab; Prostate; KidneyLeucémie; Aspergillus fumigatus; Alemtezumab; Prostate; Rein